Weekly Paclitaxel After Failure of Gemcitabine in Pancreatic Cancer Patients with Malignant Ascites: A Retrospective Study

Division of Gastrointestinal Oncology, Shizuoka Cancer Center, 1007, Nagaizumi, Shizuoka 411-8777, Japan.
Japanese Journal of Clinical Oncology (Impact Factor: 1.75). 12/2010; 40(12):1135-8. DOI: 10.1093/jjco/hyq117
Source: PubMed

ABSTRACT Peritoneal metastasis is one of the major sites of disease progression of pancreatic cancer. There have been few trials in the second-line setting after gemcitabine failure because patients can hardly be candidates for chemotherapy after failure in the first-line chemotherapy, especially those with malignant ascites. The safety and efficacy of weekly paclitaxel therapy was evaluated for pancreatic cancer patients with malignant ascites in this retrospective study.
The subjects of this retrospective study were 23 advanced pancreatic cancer patients with malignant ascites who received weekly paclitaxel therapy after gemcitabine failure. Paclitaxel (80 mg/m(2), div. for 1 h) was administered on Days 1, 8 and 15, every 4 weeks.
While the disease control rate was 35%, decrease of ascites was obtained in 30% of the patients and ascites control rate was 61%. The median survival time was 101 days. Toxicities were mild, although one treatment-related death occurred.
Weekly paclitaxel therapy may be useful treatment option for pancreatic cancer patients with malignant ascites after gemcitabine failure.

  • [Show abstract] [Hide abstract]
    ABSTRACT: The past few decades have seen virtually no treatment advances for patients with metastatic pancreatic cancer. Clinical hallmark features of pancreatic ductal adenocarcinoma (PDA) include late symptom onset, invasive growth, early liver and lymph node metastasis, and resistance to available chemotherapies. nab-Paclitaxel (Abraxane®) is generated through high-pressure homogenization of human albumin and conventional paclitaxel resulting in non-covalently bound, water-soluble albumin-paclitaxel particles with an approximate diameter of 130 nm. Results from the recently completed Metastatic Pancreatic Adenocarcinoma Trial (MPACT) (phase III trial) showed a significant survival benefit for patients treated with nab-paclitaxel in combination with gemcitabine, and this treatment regimen is currently being implemented in national and international guidelines for PDA patients. Therefore, this regimen provides a much needed vantage point of attack for this recalcitrant tumor offering potential new hope for our patients. Mechanisms such as stromal depletion, selective intratumoral accumulation, synergism with gemcitabine metabolism and secreted protein acidic and rich in cysteine (SPARC) mediated anti-tumor activity have been suggested for nab-paclitaxel. This review discusses the clinical and experimental advances of nab-paclitaxel in pancreatic cancer.
    Zeitschrift für Gastroenterologie 03/2014; 52(4). DOI:10.1055/s-0034-1366002 · 1.67 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Here, we reported an interim analysis of feasibility and safety in the first 10 cases of 30 cases in a phase II trial of intravenous and intraperitoneal paclitaxel combined with S-1 for gemcitabine-refractory pancreatic cancer with malignant ascites. Paclitaxel was administered intravenously at 50 mg/m(2) and intraperitoneally at 20 mg/m(2) on days 1 and 8 every 3 weeks, and S-1 was administered at 80 mg/m(2)/day for 14 consecutive days, followed by 7-day rest. Between April 2011 and February 2012, ten patients were enrolled. A partial response was achieved in two patients (20 %) and a disease control rate of 50 %. The median time to progression and overall survival were 2.1 and 3.4 months, respectively. Malignant ascites was completely resolved in two patients (20 %). Major grade 3/4 adverse events were myelosuppression including neutropenia (50 %) and catheter-related infection (10 %). This novel combination chemotherapy was feasible and showed promising results in pancreatic cancer patients with malignant ascites (clinical trial registration number: UMIN000005306).
    Journal of Gastrointestinal Cancer 03/2014; DOI:10.1007/s12029-014-9603-1
  • [Show abstract] [Hide abstract]
    ABSTRACT: Paclitaxel has wide application in anti-cancer therapy but was never considered an efficacious agent in pancreatic cancer. A review of the experience with the Cremaphor (Cre) formulation hinted paclitaxel's activity in pancreatic cancer but the early development was hampered by significant toxicities such as neutropenia and infection at clinically tolerable doses. However, such efficacy was confirmed in the recently completed phase III MPACT trial where the addition of nab-paclitaxel to gemcitabine significantly improved the survival of metastatic pancreatic cancer patients. Several other Cremaphor-free formulations of paclitaxel had also been evaluated in pancreatic cancer and the reasons for the success of the albumin nanoparticulate are examined here. In the era of biological and molecularly-targeted agents, the success of nab-paclitaxel in the recalcitrant pancreatic cancer is a timely reminder of the importance and relevance of pharmacology and novel drug delivery technology in the development of anti-cancer drugs.
    Clinical Cancer Research 08/2013; 19(20). DOI:10.1158/1078-0432.CCR-13-1356 · 8.19 Impact Factor